Psilocybin & Microdosing Statistics 2026: The Complete Data Guide

Last updated: April 27, 2026

The most comprehensive collection of cited statistics on psilocybin mushrooms, microdosing, clinical research, and policy in 2026. Every number on this page links to its primary source — clinical trial publications, government data, peer-reviewed surveys, and verified news. Updated as new data emerges.

If you’re a journalist, researcher, or curious reader looking for accurate, sourced data on the psychedelic renaissance, this is your reference page. Bookmark it. Cite it. Send corrections — we update this annually.

Quick navigation: 1. Usage & Adoption 2. Clinical Research 3. Microdosing Specifically 4. Brain Science 5. Safety Data 6. Oregon & State Programs 7. Federal Policy & Legality 8. Ibogaine 9. Market Data 10. Historical Context

Big Picture: The Stats That Matter Most {#headlines}

If you read nothing else on this page, these are the numbers that define the 2026 psilocybin landscape:

10 million American adults microdosed in 2025 (RAND Survey) 80% of long-term smokers were biologically verified abstinent at 6 months after psilocybin therapy (Johns Hopkins, 2014) 48% of alcohol use disorder patients stopped drinking entirely 8 months after psilocybin therapy (NYU, 2022) 67% of psilocybin therapy patients remained in remission from depression for at least 5 years (Johns Hopkins, 2024) 641 therapeutic index for psilocybin (vs. aspirin = 199, nicotine = 21) $50 million Texas committed to ibogaine research — the largest publicly-funded psychedelic research initiative in history (June 2025) April 18, 2026 — President Trump signed an Executive Order accelerating psychedelic research and FDA pathways, with Joe Rogan present at the signing Three states now have legal therapeutic psilocybin programs: Oregon, Colorado, and New Mexico (signed April 8, 2025)

Sources for each of these numbers are linked in their full sections below.

1. Usage & Adoption {#usage}

How many Americans use psilocybin and microdose?

• 8.4 million U.S. adults have microdosed psilocybin in their lifetime. Among the 12.1% of U.S. adults with lifetime psilocybin use, 26.5% microdosed the last time. (Priest et al., Addiction 2026)

• ~10 million U.S. adults microdosed in 2025. RAND Psychedelics Survey 2025 (n=10,122 nationally representative adults). Approximately 3.7% of the U.S. adult population microdosed psilocybin, LSD, or MDMA in the past year. (RAND, January 2026)

• ~8 million Americans used psilocybin in 2024 (2.8% of the population age 12+). First year the National Survey on Drug Use and Health (NSDUH) included psilocybin-specific questions. (NSDUH 2024 / UC San Diego, April 2026)

• Psilocybin use grew approximately 37.5% year-over-year, from ~8 million U.S. adults (2023) to ~11 million (2024). (RAND 2025 Survey)

• 69% of past-year psilocybin users microdosed at least once in 2025 — up from 47% in 2023. (RAND 2025)

• Nearly half of all 200+ million days of psilocybin use in the past year involved microdosing. (RAND 2025)

Demographics

• 18-25 year-olds are 1.4x more likely to use psilocybin than 35-49 year-olds. Males 1.7x females. White respondents 2.5x Black, 1.4x Hispanic. (NSDUH 2024)

• ~1 in 15 young adults (ages 19-30) reported past-year hallucinogen microdosing. Monitoring the Future / NSDUH analysis. (Epidemiology of Hallucinogen Microdosing study, PMC)

• Average age of microdosers: 33 years old. Distribution: 31% are 18-25, 30% are 26-35, 19% are 36-45. (PMC review)

• Exclusive microdosers skew older and more female. Mean age 46.4 (vs. 42.0 for combined micro/macro users). 68.4% female (vs. 44.7% in combined-use group). (Global Trends in Psychedelic Microdosing, PubMed 2024)

Search Trends

• 1,250% rise in microdosing-related Google searches from 2015-2023 — over 3 million searches in 2023 alone. (JAMA Health Forum study)

• Oregon, Colorado, and Washington had the highest microdose search growth. Permissive substance-use policies explained 27% of variance in monthly search rates. (JAMA Health Forum)

2. Clinical Research {#clinical}

Depression — The Strongest Evidence Base

• Johns Hopkins MDD Trial (2020): 71% of participants had clinically significant response and 54% met criteria for remission of depression at 4-week follow-up. Effect size approximately 4x larger than typical antidepressant trials. n=24 adults with major depressive disorder. (Davis AK et al., JAMA Psychiatry, November 2020)

• Johns Hopkins 12-Month Follow-Up: 75% response rate and 58% remission at month 12. (Gukasyan et al., J Psychopharmacology 2022)

• Johns Hopkins 5-Year Follow-Up (2024): 67% of participants remained in remission from depression for at least five years post-treatment. 18 of 24 original participants completed long-term follow-up. (Davis et al., J Psychedelic Studies 2024)

• Imperial College Psilocybin vs. Escitalopram (2021): 70% response rate (psilocybin) vs. 48% (escitalopram, an SSRI). 57% remission vs. 28%. Phase 2 RCT, 59 patients with moderate-to-severe MDD over 6 weeks. (Carhart-Harris et al., NEJM April 15, 2021)

• Compass Pathways COMP360 Phase 2b (2022): Single 25 mg dose of synthetic psilocybin in treatment-resistant depression: 37% response at week 3. 233 patients across 22 sites in 10 countries — largest psilocybin trial to that date. (Goodwin et al., NEJM November 2022)

• Compass Pathways Phase 3 COMP005 (2025) and COMP006 (Feb 2026): Both achieved primary endpoint with p<0.001. MADRS differences of -3.6 and -3.8 respectively. NDA submission planned Q4 2026. (Compass IR)

• Usona Institute Phase 2 (2023): Single 25 mg psilocybin dose produced rapid, sustained antidepressant effect over 6 weeks. 104 adults, 11 US sites. (Raison et al., JAMA August 2023)

• 2024 Meta-Analysis (Frontiers in Psychiatry): 9 RCTs, n=596. Pooled effect size SMD = -0.78, p<0.001. Pooled remission: 45% (psilocybin) vs. 22% (comparators). (Yu et al., Frontiers in Psychiatry 2024)

Addiction — The “Holy Shit” Numbers

• Johns Hopkins Smoking Cessation (2014): 80% (12 of 15) of long-term smokers were biologically verified abstinent at 6-month follow-up after psilocybin-assisted therapy. Compared to typical cessation therapies that achieve under 35%. 67% remained abstinent at 12+ months. (Johnson et al., J Psychopharmacology 2014; PMC long-term follow-up)

• NYU Alcohol Use Disorder Trial (2022): Heavy drinking days reduced from 23.6% (placebo) to 9.7% (psilocybin) over 32 weeks — an 83% reduction in heavy drinking from baseline. 48% of psilocybin participants stopped drinking entirely at 8 months — double the placebo rate. 95 adults with AUD. (Bogenschutz et al., JAMA Psychiatry August 2022)

End-of-Life and Cancer Distress

• NYU/Johns Hopkins Parallel Cancer Trials (2016): 60-80% of patients with life-threatening cancer showed clinically significant reductions in anxiety and depression after a single psilocybin dose. Effects sustained ~8 months. Two studies published simultaneously. (Ross et al. & Griffiths et al., J Psychopharmacology December 2016)

Other Conditions Showing Promise

• Yale OCD Pilot (2006): All 9 patients showed acute reductions in OCD symptoms ranging 23-100% on Y-BOCS during testing sessions. Two-thirds maintained ≥50% Y-BOCS reduction at 24 hours. (Moreno et al., J Clin Psychiatry 2006)

• Anorexia Nervosa Phase 1 (2023): 90% of 10 female participants ranked their psilocybin session in their top 5 most meaningful life experiences. 70% reported quality-of-life improvements. 4 of 10 showed clinically significant reductions in eating disorder psychopathology. (Peck et al., Nature Medicine July 2023)

• Veterans with Treatment-Resistant Depression (2024): 60% met response criteria, 53% met remission criteria at 3 weeks. Co-morbid PTSD did not affect outcomes. (Davis et al., J Affective Disorders 2024)

• Yale Cluster Headache Trial (2024): Repeated pulse reduced attack frequency from 18.4 to 9.8 attacks per week (p=0.013) — about 50% reduction regardless of initial response. (Schindler et al., J Neurological Sciences 2024)

The Mystical Experience

• Griffiths 2006 Landmark Study: Two-thirds of participants rated the psilocybin session among the 5 most personally meaningful and spiritually significant events of their lives — comparable to the birth of a first child or death of a parent. 36 hallucinogen-naïve volunteers. Single high dose. (Griffiths et al., Psychopharmacology 2006)

The Scope of Active Research

• 134+ interventional psilocybin clinical trials registered as of April 2024, studying 54 distinct potential indications. 102 of these registered in the last 5 years. Zero marketing approvals yet (Schedule I status remains the regulatory barrier). (Siegel et al., PMC 2024)

3. Microdosing Specifically {#microdosing}

What Microdosers Report

• 71.84% of microdosers with depression reported improvement in depressive symptoms. (Hutten et al. 2019, Front Psychiatry)

• 92.9% of survey respondents reported improved mood from microdosing. (Anderson et al., Harm Reduction Journal 2019)

• 44% of microdosers perceived “much better” mental health from the practice. (Scientific Reports 2021)

• 66.56% reported improved sociability. (Hutten et al. 2019)

• Reported lifestyle improvements: anxiety 59.2%, meditative practice 49.1%, exercise 49.1%, eating habits 36.0%, sleep 28.8%. (PMC review)

The Placebo Problem (Critical Caveat)

• Imperial College “self-blinding” study (2021): Largest placebo-controlled microdosing trial. n=191. Both microdose AND placebo groups improved on all psychological measures; no significant between-group differences. The conclusion: benefits explained by expectancy/placebo effect. (Szigeti et al., eLife 2021)

• Cavanna et al. 2022 RCT: Active dose produced detectable subjective effects only when participants correctly guessed condition. No measurable improvements in well-being, creativity, or cognitive function vs. placebo. (Translational Psychiatry 2022)

• Polito & Liknaitzky review (2024): Reviewed all microdose research through April 2021. Belief about what was taken predicted outcomes more strongly than actual experimental condition. (J Psychopharmacology 2024)

Side Effects

• ~1 in 5 microdosers report negative side effects (mostly psychological). Physiological discomfort: 18.0%. Increased anxiety: 6.7%. (Anderson et al. 2019)

• Main reason people quit microdosing: “It didn’t work” — absence of self-rated efficacy was the primary reason for stopping, NOT side effects. (Hutten et al. 2019)

Protocols Used

• Fadiman Protocol (1 day on, 2 days off) is the most popular schedule. Originated in Fadiman’s 2011 book The Psychedelic Explorer’s Guide; popularized by 2015 Tim Ferriss podcast. (Microdosing Institute)

• Stamets Stack (4 days on, 3 days off) combines 100-200 mg psilocybin + lion’s mane + niacin (vitamin B3). Coined the term “stacking.” (Microgenix breakdown)

• Standard psilocybin microdose: 0.1-0.3g (100-300 mg) of dried Psilocybe cubensis — roughly 5-10% of a full psychoactive dose.

• LSD microdosers typically dose ~10 mcg, psilocybin users ~0.5g — typically 2-4 times per week. (Hutten et al. 2019)

Why People Microdose

• Primary motivations (Hutten 2019): Mental health improvement 40%, personal development 31%, cognitive enhancement 18%, performance enhancement 37%, self-treating depression 21%, self-treating anxiety 7%.

• ADHD users: 53% of ADHD microdosers had previously used and stopped conventional ADHD medication, primarily due to side effects. (van Oorsouw et al., Eur Psychiatry 2024)

4. Brain Science {#brain}

• Psilocybin acts as a partial agonist at the serotonin 5-HT2A receptor. Receptor occupancy reaches 63-75% in default mode network regions at therapeutic doses. (Madsen et al., Frontiers in Neuroergonomics 2021)

• Default Mode Network disruption: Psilocybin reduces integrity of the DMN — the brain network associated with self-referential rumination and the proposed driver of depression’s “stuck” state. DMN disruption correlates with reported ego-dissolution and antidepressant response. (Carhart-Harris et al., Scientific Reports 2017)

• Dendritic Spine Growth: Single dose of psilocybin produces rapid (within 24 hours) and persistent (≥1 month) growth of dendritic spines in mouse frontal cortex. Spine density increases ~10%, with about half the new spines becoming stable functional synapses by day 7. (Shao et al., Neuron 2021, Yale)

• BDNF and TrkB Signaling: Psilocin promotes neuroplasticity by activating BDNF-TrkB-mTOR signaling. Psychedelics show 1,000-fold greater binding affinity for TrkB than SSRIs, partially explaining the rapid antidepressant response. (Moliner et al., Nature Neuroscience 2023)

5. Safety Data {#safety}

• Therapeutic index ≈ 641. Compare: aspirin = 199, nicotine = 21. Estimated human lethal dose: 2,000-6,000 mg — roughly 1,000x the effective therapeutic dose (6 mg) and 200x typical recreational dose (10-30 mg). (Hofmann vs. Paracelsus systematic review, PMC 2023)

• No deaths attributable to psilocybin in clinical studies. Serious adverse events rare and largely confined to participants with pre-existing depression or suicidal history. (JAMA Psychiatry meta-analysis 2024)

• Cardiovascular safety: Mild, transient elevations in heart rate and blood pressure that rarely require intervention. Minimal impact on QTc intervals at therapeutic doses. (PMC 2023)

• Abuse potential: Limited reinforcing effects (the hallmark of addictive substances). Per CSA 8-factor analysis, Schedule IV may be appropriate if approved as medicine. (Johnson et al., Neuropharmacology 2018)

• Standard contraindications (clinical trials and Oregon’s regulated program): personal or family history of psychotic disorders (schizophrenia, schizoaffective), Bipolar I, lithium use within 30 days (seizure risk), active suicidality, severe cardiac conditions. MAOIs pose serotonin syndrome risk; SSRIs may blunt effects but do not. (UCSF Translational Psychedelic Research)

6. Oregon & State Programs {#programs}

Oregon Measure 109 — The First Legal Program

• ~16,000 clients have received psilocybin services in Oregon since 2023. $1.7M+ revenue. 37,000+ psilocybin products sold. Q1 2025 alone served 1,509 clients. (Oregon Health Authority dashboard)

• >99.6% incident-free session rate. Of 1,509 Q1 2025 clients, only 6 reported adverse reactions (2 severe behavioral, 3 medical, 1 post-session). (Oregon Psilocybin Services)

• Demographics: Majority earn over $95,000 per year. Most are over age 45. Most common reasons: depression, anxiety, PTSD, personal growth. (OPB News on OHA data)

• Service centers: Of 35 originally licensed, only 23 operational as of 2025 (12 closures). 377 active facilitators. Annual licensing fee: $10,000.

• Sessions cost $1,500-$3,400 depending on center, dose, and duration.

• First peer-review-track real-world outcomes study (Feb 2026): n=91 Oregon clients. Significant improvements at 30 days post-session in depression (PHQ-8), anxiety (GAD-7), and well-being (WHO-5). All p<0.001. Improvements held even among 46.6% of clients concurrently using psychiatric medication. (medRxiv preprint)

Colorado Proposition 122

• 34+ state-licensed healing centers operational as of early 2026. Boulder has 3 (Happy Rebel, Chariot, Psychedelic Growth). Denver’s Center Origin was the first standard licensed center. (Boulder Reporting Lab)

New Mexico — Third State

• Signed April 8, 2025. First state to legalize via legislation rather than ballot. Medical Psilocybin Act covers treatment-resistant depression, PTSD, substance use disorders, end-of-life care. Program could launch late 2026.

Other State Action

• New Jersey: January 2026, $6 million two-year psychedelic research initiative.
• Massachusetts: 2024 ballot Question 4 rejected 57.1% no. New legislative bills now progressing.
• Active legislation 2026: Connecticut, Vermont, Utah, Missouri, others.

Decriminalized Cities (Verified List as of 2026)

California: Oakland, Santa Cruz, Berkeley, San Francisco, Eureka, Arcata Michigan: Detroit, Ann Arbor, Hazel Park, Ferndale Colorado: Denver Massachusetts: Cambridge, Somerville, Northampton, Easthampton, Salem, Amherst, Provincetown Washington: Seattle, Tacoma (January 2025), Port Townsend, plus King County (March 2026) District of Columbia: Initiative 81

7. Federal Policy & Legality {#policy}

Trump Psychedelics Executive Order — April 18, 2026

• Title: “Accelerating Medical Treatments for Serious Mental Illness”
• Joe Rogan was present at the signing ceremony. Rogan reportedly texted Trump about ibogaine. Trump’s response: “Sounds great. Do you want FDA approval? Let’s do it.” (Fortune coverage)

What the EO does:

• Directs FDA to issue Commissioner’s National Priority Vouchers to psychedelic drugs with Breakthrough Therapy designations
• Directs the Attorney General to initiate DEA rescheduling reviews after Phase 3 trial completion so rescheduling can happen quickly upon FDA approval
• Allocates $50 million via ARPA-H to match state government investments in psychedelic research
• Establishes a Right-to-Try pathway for eligible patients to access investigational psychedelics (including ibogaine) that have met basic safety requirements
• Directs HHS/FDA to collaborate with VA on clinical trial access for veterans

What the EO does NOT do (critical):

• It does NOT reschedule psilocybin or any psychedelic
• It does NOT legalize or decriminalize mushrooms for the public
• Psilocybin, ibogaine, MDMA, and LSD all remain Schedule I under federal law
• Presidents legally cannot unilaterally reschedule a substance — that requires DEA/HHS scientific review

Three companies received Commissioner’s National Priority Vouchers: 1. Compass Pathways — psilocybin for treatment-resistant depression 2. A second psilocybin program for major depressive disorder 3. Methylone for PTSD

(Sources: White House EO text; White House Fact Sheet; NPR; TIME explainer)

Cannabis Rescheduling — Schedule I → Schedule III (April 22, 2026 effective)

• December 18, 2025: Trump signed EO directing AG to expedite marijuana rescheduling
• April 22, 2026: Acting AG Blanche issued final order placing two specific categories of marijuana into Schedule III: (1) FDA-approved marijuana products, and (2) marijuana under a state-issued license for medical purposes only
• June 29, 2026: DEA expedited hearing scheduled to consider rescheduling marijuana as a whole (broader than just medical)

Critical: Recreational marijuana remains Schedule I even under state legalization programs. Synthetically-derived THC and unlicensed activity remain Schedule I. State-licensed medical operators are no longer subject to IRC Section 280E tax penalty.

FDA Breakthrough Therapy Designations

• October 2018: Compass Pathways received the first FDA Breakthrough Therapy Designation for psilocybin therapy (treatment-resistant depression). (Compass IR)

• November 2019: Usona Institute received the second Breakthrough Therapy Designation for psilocybin (major depressive disorder — broader population). (Usona Institute)

• What it means: FDA recognizes preliminary evidence of substantial improvement over available therapy. Provides intensive guidance, eligibility for accelerated approval and rolling review. Drugs with Breakthrough designation see ~30% reduction in clinical development time.

International Status

• Australia (July 1, 2023): First country to allow psilocybin to be prescribed by authorized psychiatrists for treatment-resistant depression. MDMA simultaneously approved for PTSD. (TGA media release)

• Canada: Psilocybin Schedule III. Section 56 exemptions allow medical/end-of-life use. 57 grey market psilocybin dispensaries operating in 15 cities as of May 2024. (Canadian J Public Health 2026)

• Netherlands: Psilocybin truffles (sclerotia) legal, sold in smart shops. Dried mushrooms banned 2008 — truffles were not.

• Jamaica: No laws against psilocybin mushrooms. Retreat centers operate legally.

• Brazil: Psilocybin mushrooms not scheduled.

• Portugal: All drugs decriminalized for personal use since 2001.

8. Ibogaine — The Parallel Story {#ibogaine}

Texas Ibogaine Initiative — $50 Million

• June 2025: Texas SB 2308 signed — $50 million from the Texas Legislature, the largest publicly-funded psychedelic research initiative in history.
• Authorizes Texas Health and Human Services Commission to provide state matching funds for FDA-approved clinical trials of ibogaine for opioid use disorder, depression, and PTSD.
• March 31, 2026: Texas pivoted to running its OWN trials after failing to find a pharmaceutical partner.
• IMPACT consortium: UTHealth Houston (lead), UT Galveston, Texas Tech, UT Austin, Texas A&M, North Texas, Baylor College of Medicine, JPS Health Network. (Texas Tribune)

Stanford Ibogaine Research — Veterans

• Stanford / Nature Medicine (Williams et al., January 2024): Magnesium-ibogaine therapy in 30 special operations veterans with TBI. Findings at 1 month post-treatment:

- PTSD symptoms: average 88% reduction - Depression: average 87% reduction - Anxiety: average 81% reduction - Increased cortical thickness, subcortical expansion, reduced predicted brain age

• Quote from lead author Dr. Nolan Williams: “No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury.” (Stanford Medicine; Nature Medicine)

Veterans Movement

• VETS (Veterans Exploring Treatment Solutions): >1,000 veteran/athlete treatments. ~250 apply per month. Secured >$124M in public funding for psychedelic research. Co-founder Marcus Capone (retired Navy SEAL) was at the White House for the April 18, 2026 EO signing.

• Mexico clinics combined (Ambio, The Mission Within, Beond): ~3,000 U.S. veterans treated in past decade. Veteran suicide context: ~20 daily.

Ibogaine Safety

• 19 documented fatalities (1990-2008) temporally associated with ibogaine ingestion. 6 of 19 were acute heart failure or cardiopulmonary arrest. Average time from ingestion to death: ~24 hours.
• Cardiac risk mechanism: QT prolongation → Torsades de Pointes. Ibogaine blocks hERG potassium channels.
• Safe-use protocols: Continuous ECG monitoring, magnesium pre-loading (the Stanford protocol), pre-screening for cardiac risk factors. (NIH/PMC review)

DemeRx — FDA Trial Greenlight

• April 2026: FDA accepted DemeRx’s IND application for DMX-1001 (oral noribogaine) for Phase I/II study in alcohol use disorder. First time FDA has allowed U.S. clinical study of an ibogaine derivative. (Business Wire)

International Ibogaine Access

9. Market Data {#market}

• Global psychedelic drugs market: $4.78B in 2025 → projected $5.48B in 2026. Coherent Market Insights projects $11.07B by 2033 at 14.0% CAGR. (Coherent Market Insights)

• U.S. psychedelic mushroom products market: $1.95B in 2025 → projected $2.26B (2026) → $8.46B by 2035. (Towards FnB Insights)

• Microdosing products: 22% of psychedelic mushroom market share in 2025; growing at 18.9% CAGR.

• U.S. functional mushroom market: Projected to reach $8.57B by 2030 (12.1% CAGR 2024-2030). (Grand View Research)

• Canadian grey market: 57 psilocybin dispensaries operating in 15 cities (May 2024). 2.6% of Canadians live within 1 km of a dispensary. 100% of online dispensaries sold microdose capsules. Single-vendor revenue ~$50K/month observed. (Canadian J Public Health 2026)

Global Disease Burden Context

• ~280 million people worldwide live with depression (WHO). Depression is projected to be the leading global disease burden by 2030. ~301 million live with anxiety disorders. (WHO)

• U.S. Treatment-Resistant Depression burden: 8.9 million U.S. adults receive medication treatment for MDD annually. 2.8 million (30.9%) have treatment-resistant depression. Total annual U.S. economic burden of treated MDD: $92.7 billion, with $43.8 billion (47.2%) attributable to TRD. (Zhdanava et al., J Clin Psychiatry 2021)

10. Historical Context {#history}

Pre-Western Discovery

• Aztec teonanácatl = “divine mushroom.” (Note: the popular translation “flesh of the gods” is a near-mistranslation — the Nahuatl word for flesh is similar but distinct.) Documented in Bernardino de Sahagún’s Florentine Codex (compiled 1547-1590).

• Guatemalan mushroom stones: Pre-classic Maya period (1000-500 BCE). Borhegyi documented ~50 sites across Mexico, Guatemala, El Salvador with mushroom stone artifacts.

• The Tassili “mushroom shaman” rock art (Algeria, c. 7000-9000 BCE) is widely cited but the iconic image was drawn by Kat Harrison from a photograph, not the original art. Recent scholarship is highly skeptical the figures depict mushrooms at all.

Western Rediscovery

• R. Gordon Wasson (J.P. Morgan banker) participated in a velada with Mazatec curandera Maria Sabina on June 29-30, 1955 in Huautla de Jiménez, Oaxaca.

• “Seeking the Magic Mushroom” appeared in Life Magazine on May 13, 1957 — the article that introduced psilocybin mushrooms to mass Western audiences.

• CIA MK-Ultra Subproject 58 funded Wasson’s 1956 follow-up expedition with $2,000 (~$20,000 today) disguised as a Geschickter Fund grant. CIA documents describe Wasson as “unwitting.” (Logos Media documentation)

• Albert Hofmann (the chemist who synthesized LSD in 1938) isolated psilocybin and psilocin in 1958 at Sandoz Laboratories in Basel.

• Sandoz marketed psilocybin as “Indocybin” (1960) — 2 mg pills sold to physicians worldwide for psychotherapy research.

The Harvard Era

• Harvard Psilocybin Project founded 1960 by Timothy Leary and Richard Alpert.

• Marsh Chapel “Good Friday” Experiment (April 20, 1962): 9 of 10 in psilocybin group reported mystical experiences vs. 1 of 10 placebo. Caveat: Pahnke initially failed to disclose acute anxiety reactions; one subject required Thorazine.

• By the mid-1960s, more than 40,000 patients had received psychedelics in clinical trials. Over 1,000 scientific papers published. (LSD + psilocybin combined.)

• Harvard fired Leary and Alpert in Spring 1963.

Prohibition

• Controlled Substances Act (October 27, 1970): Nixon signed. Psilocybin and psilocin → Schedule I. Research effectively halted for decades.

• The famous “Nixon called Leary the most dangerous man in America” quote has no documented source. It became a 2018 book title (Minutaglio & Davis), but historians cannot find Nixon ever actually saying it.

• UN Convention on Psychotropic Substances (1971) placed psilocybin/psilocin in Schedule I globally. Important nuance: the Convention controls the chemical compounds, NOT the natural mushrooms — which is why the Netherlands could exploit the truffle loophole.

Maria Sabina’s Story

• After Wasson’s Life article, the Mazatec community blamed Maria Sabina for revealing sacred knowledge. Her house was burned. Her son was murdered. She was briefly jailed. She died in poverty and malnutrition at age 91 in November 1985.

• The Mazatec community holds none of the patents and receives no financial benefit from the modern psychedelic industry. This is now central to discussions of “psychedelic colonialism.”

The Renaissance

• Roland Griffiths' 2006 Hopkins study — the publication that re-legitimized psilocybin clinical research after a 30+ year gap.

• MAPS founded 1986 (Rick Doblin). Heffter Research Institute founded 1993 (David Nichols). Beckley Foundation founded 1998 (Amanda Feilding).

• Michael Pollan’s “How to Change Your Mind” (May 2018 book → July 12, 2022 Netflix series): Mass cultural mainstreaming of psychedelic discourse.

• Denver became first U.S. city to decriminalize psilocybin in May 2019 (narrow 50.6% margin).

• Australia became first nation to allow prescribed psilocybin (July 1, 2023).

Methodology & Updates

This page is compiled from peer-reviewed journal publications, government data dashboards, sponsor press releases tied to peer-reviewed publications, university press offices, and verified news from established outlets. Every numerical claim links to a primary source.

Updated annually. Last update: April 27, 2026.

Found an error or have a stat to add? Email research@kindstranger.club. We update this page as research emerges.

For journalists: This page is maintained as a resource for accurate citation. You’re welcome to use any data on this page in your reporting — please cite the original primary source where possible. If you cite Kind Stranger as the aggregator, please link to this page.

For researchers: Bibliography is current as of compilation date. We’re building a parallel academic citation list — contact us if you need it.

Related Kind Stranger resources:

• Psilocybin: A Complete Deep-Dive
• Magic Mushroom Strain Guide
• Microdosing Complete Guide
• Set and Setting Explained
• Psilocybin Legality in Canada
• The Apothecary — Full Library